Citations

Clear

904 citation(s) found for "Gordon, S".

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
Pardanani, Animesh , Brockman, Stephanie R., Paternoster, Sarah F., Flynn, Heather C., Ketterling, Rhett P. , Ho, Ching-Liang, Li, Chin‐Yang, Dewald, Gordon W., Tefferi, Ayalew , Lasho, Terra L. , Li, Chin‐Yang, Ketterling, Rhett P

Mayo Clinic

Blood | July 30, 2004 | Volume: 104 | Issue: 10 | Pages: 3038-3045

10.1182/blood-2004-03-0787 | PMID 15284118 Get It

Abstract A novel oncogenic mutation (FIP1L1-PDGFRA), which results in a constitutively activated platelet-derived growth factor receptor-α (PDGFRA), has been invariably associated with a primary eosinophilic disorder. The current study examines both the prevalence and the associated clinicopathologic features of this mutation in a cohort of 89 adult patients presenting with an absolute eosinophil count (AEC) of higher than 1.5 × 109/L. A fluorescence in situ hybridization (FISH)–based strategy was used to detect FIP1L1-PDGFRA in bone marrow cells. None of 8 patients with reactive eosinophilia displayed the abnormality, whereas the incidence of FIP1L1-PDGFRA in the remaining 81 patients with primary eosinophilia was 14% (11 patients). None (0%) of 57 patients with the hypereosinophilic syndrome (HES) but 10 (56%) of 19 patients with systemic mast cell disease associated with eosinophilia (SMCD-eos) carried the specific mutation. The bone marrow mast cell infiltration pattern in FIP1L1-PDGFRA+ SMCD-eos was distinctly diffuse with loose tumoral aggregates. Treatment with low-dose imatinib (100 mg/d) produced complete and durable responses in all 8 FIP1L1-PDGFRA+ cases treated. In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis.
Conservative Management of Acoustic Neuroma: An Outcome Study
Deen, Gordon H., Ebersold, Michael J., Harner, Stefphen G., Beatty, Charles W., Marion, Mitchell S., Wharen, Robert E. , Green, J. Douglas, Quast, R.N. Lynn, Sg, Harner, Quast, Lynn M.

Mayo Clinic

Neurosurgery | July 30, 2004 | Volume: 39 | Issue: 2 | Pages: 260-266

10.1097/00006123-199608000-00005 | PMID 8832662 Get It

Difficulties with the “N + 7 Rule” in endoscopic anterior cruciate ligament reconstruction
Pagnano, Mark W., Kim, Chang-Woo , Huie, Gordon, Pagnano, Mark W. , Scott, W. Norman

Mayo Clinic

Arthroscopy | June 2, 2004 | Volume: 13 | Issue: 5 | Pages: 597-599

10.1016/s0749-8063(97)90186-9 | PMID 9343648 Get It

Abstract In an effort to facilitate the use of interference screw fixation in the tibia, a method to orient the tibial tunnel termed the “N + 7 Rule” was prospectively applied to 60 consecutive endoscopic anterior cruciate ligament reconstructions performed by a single surgeon. Four cases were excluded because a breach in the described protocol for application of the N + 7 rule was identified at the time of the operation. Of the remaining 56 cases, 28 (50%) were fixed with an interference screw on the tibia, whereas 28 (50%) required fixation with sutures tied over a post. The 28 cases not amenable to interference screw fixation included 17 cases in which the tibial tunel was too long and 11 cases in which the tunnnel was too short. It appears that the applicability of the N + 7 rule to an individual surgeon's practice may be altered by small variations in operative technique.
Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemias
Paietta, Elisabeth , Ferrando, Adolfo A. , Bennett, John M. , Racevskis, Janis, Dewald, Gordon W., Rowe, Jacob M. , Wiernik, Peter H. , Tallman, Martin S. , Look, A. Thomas , Neuberg, Donna , Lazarus, Hillard M.

Mayo Clinic

Blood | March 29, 2004 | Volume: 104 | Issue: 2 | Pages: 558-560

10.1182/blood-2004-01-0168 | PMID 15044257 Get It

Abstract Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/KIT and cytoplasmic CD3 (CD117/KIT+ ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT+ cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL. (Blood. 2004;104:558-560)
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
Gordon, Leo I. , Molina, Arturo , Emmanouilides, Christos, Raubtischek, Andrew, Darif, Mohamed, Schilder, Russell J., Wiseman, G. , White, Christine A., Witzig, Thomas E. , Gordon, Leo I

Mayo Clinic

Blood | March 16, 2004 | Volume: 103 | Issue: 12 | Pages: 4429-4431

10.1182/blood-2003-11-3883 | PMID 15016644 Get It

Abstract We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma. (Blood. 2004;103:4429-4431)
Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
Greenberg, Peter L. , Advani, Ranjana H. , Tallman, Martin S. , Šikić, Branimir I. , Letendre, Louis, Dugan, Kathleen, Lum, Bert L., Chin, David L. , Dewald, Gordon W., Paietta, Elisabeth , Bennett, John M. , Rowe, Jacob M. , Lee, Sandra J. , Advani, Ranjana H

Mayo Clinic

Journal of Clinical Oncology | March 12, 2004 | Volume: 22 | Issue: 6 | Pages: 1078-1086

10.1200/jco.2004.07.048 | PMID 15020609 Get It

Purpose To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Patients and Methods A phase III randomized study was performed using valspodar plus mitoxantrone, etoposide, and cytarabine (PSC-MEC; n = 66) versus MEC (n = 63) to treat patients with relapsed or refractory AML and high-risk MDS. Results For the PSC-MEC versus MEC arms, complete response (CR) was achieved in 17% versus 25% of patients, respectively (P = not significant). For patients who had not received prior intensive chemotherapy (ie, with secondary AML or high-risk MDS), the CR rate was increased—35% versus 15% for the remaining patients (P = .018); CR rates did not differ between treatment arms. The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients’ overall survival (4.6 versus 5.4 months). The CR rates in MDR+ (69% of patients) versus MDR− patients were similar for those receiving either chemotherapy regimen (16% versus 24%). The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P = .09). Population pharmacokinetic analysis demonstrated that the clearances of mitoxantrone and etoposide were decreased by 59% and 50%, respectively, supporting the empiric dose reductions in the PSC-MEC arm designed in anticipation of drug interactions between valspodar and the chemotherapeutic agents. Conclusion CR rates and overall survival were not improved by using PSC-MEC compared to MEC chemotherapy alone in patients with poor-risk AML or high-risk MDS.
Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents
Mulatero, Paolo , Loh, Keh‐Chuan, Fardella, Carlos , Mosso, Lorena , Gómez-Sánchez, Celso E. , Veglio, Franco , Stowasser, Michael , Gordon, Richard D. , Young, William F. , Mosso, Lorena

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 4, 2004 | Volume: 89 | Issue: 3 | Pages: 1045-1050

10.1210/jc.2003-031337 | PMID 15001583 Get It

Abstract Primary aldosteronism (PA) is a common form of endocrine hypertension previously believed to account for less than 1% of hypertensive patients. Hypokalemia was considered a prerequisite for pursuing diagnostic tests for PA. Recent studies applying the plasma aldosterone/plasma renin activity ratio (ARR) as a screening test have reported a higher prevalence. This study is a retrospective evaluation of the diagnosis of PA from clinical centers in five continents before and after the widespread use of the ARR as a screening test. The application of this strategy to a greater number of hypertensives led to a 5- to 15-fold increase in the identification of patients affected by PA. Only a small proportion of patients (between 9 and 37%) were hypokalemic. The annual detection rate of aldosterone-producing adenoma (APA) increased in all centers (by 1.3–6.3 times) after the wide application of ARR. Aldosterone-producing adenomas constituted a much higher proportion of patients with PA in the four centers that employed adrenal venous sampling (28–50%) than in the center that did not (9%). In conclusion, the wide use of the ARR as a screening test in hypertensive patients led to a marked increase in the detection rate of PA.
Acute Monocytic Leukemia (French-American-British classification M5) Does Not Have a Worse Prognosis Than Other Subtypes of Acute Myeloid Leukemia: A Report From the Eastern Cooperative Oncology Group
Tallman, Martin S. , Paietta, Elisabeth , Bennett, John M. , Dewald, Gordon W., Cassileth, Peter A., Wiernik, Peter H. , Rowe, Jacob M. , Kim, Haesook T.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2004 | Volume: 22 | Issue: 7 | Pages: 1276-1286

10.1200/jco.2004.08.060 | PMID 14970186 Get It

Purpose Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biologic and clinical features. This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML, and to identify differences in M5a and M5b. Patients and Methods We reviewed all patients with AML M5 entered in three clinical trials for newly diagnosed AML conducted by the Eastern Cooperative Oncology Group between 1989 and 1998. Eighty-one patients, 21 with M5a and 60 with M5b, were identified. Results The complete remission rate was 62% for all patients with M5; 52% for patients with M5a and 65% for patients with M5b (P = .3), and 60% for the 1,122 patients with non-M5 AML entered on the same clinical trials (P = .8 for M5 v non-M5). The 3-year disease-free survival was 26% for all M5 patients; 18% for M5a and 28% for M5b (P = .31), and 33% for non-M5 patients (P = .13 for M5 v non-M5). The 3-year overall survival was 31% for all M5 patients; 33% for M5a and 30% for M5b (P = .65), and 30% for non-M5 (P = .74 for M5 v non-M5). The karyotypes of patients with AML M5 were heterogeneous. CD11b was the only leukemic cell antigen expressed differently in M5a (53%) compared to M5b (77%) to a significant degree (P = .02). Conclusion AML M5 represents an immunologically heterogeneous population similar to non-M5 AML with a prognosis that is not dependent on morphology. The disease-free survival and overall survival of patients with M5a, M5b, and non-M5 appear not to differ with currently available therapy.
Summarizing Studies of Diagnostic Test Performance
Montori, Víctor M. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Clinical Chemistry | February 23, 2004 | Volume: 49 | Issue: 11 | Pages: 1783-1784

10.1373/clinchem.2003.024935 | PMID 14578309 Get It

Constrictive Pericarditis in 26 Patients With Histologically Normal Pericardial Thickness
Talreja, Deepak, Edwards, William D. , Danielson, Gordon K., Schaff, Hartzell V. , Tajik, A. Jamil , Tazelaar, Henry D. , Breen, Jerome F., Oh, Jae K. , Tazelaar, Henry D. , Schaff, Hartzell

Mayo Clinic

Circulation | September 30, 2003 | Volume: 108 | Issue: 15 | Pages: 1852-1857

10.1161/01.cir.0000087606.18453.fd | PMID 14517161 Get It

Background— Traditionally, increased pericardial thickness has been considered an essential diagnostic feature of constrictive pericarditis. Although constriction with a normal-thickness pericardium has been demonstrated clinically by noninvasive imaging, the details of clinicopathological correlates have not been described. Methods and Results— A total of 143 patients with proven constriction underwent pericardiectomy at Mayo Clinic between 1993 and 1999. Their baseline characteristics, operative data, and pathological specimens were reviewed retrospectively. The pericardium was of normal thickness (≤2 mm) in 26 patients (18%; group 1) and was thickened (>2 mm) in 117 (82%; group 2). The most common causes of constriction in group 1 included previous cardiac surgery, chest irradiation, previous infarction, and idiopathic disease. There was little difference in symptoms and findings on physical examination between the 2 groups. Microscopically, no patient had an entirely normal pericardium. Histopathological abnormalities in group 1 were mild and focal, including fibrosis, inflammation, calcification, fibrin deposition, and focal noncaseating granulomas. Pericardiectomy was equally effective in relieving symptoms regardless of the presence or absence of increased thickness. Conclusions— Pericardial thickness was not increased in 18% of patients with surgically proven constrictive pericarditis, although the histopathological appearance was focally abnormal in all cases. When clinical, echocardiographic, or invasive hemodynamic features indicate constriction in patients with heart failure, pericardiectomy should not be denied on the basis of normal thickness as demonstrated by noninvasive imaging.